Anticipatory prescribing and end of life considerations. Dr Stephanie Lippett

Similar documents
PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

Supportive Care. End of Life Phase

Pain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

Renal Palliative Care Last Days of Life

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Syringe driver in Palliative Care

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

Care in the Last Days of Life

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

Renal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

Symptom Management Guidelines for End of Life Care

[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]

Care of the Dying Management in Severe Renal Failure

Algorithms for Symptom Management. In End of Life Care

Care of the Dying Management in Severe Renal Failure

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

End of life prescribing guidance

SYRINGE DRIVER MEDICATIONS

GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.

MND Just in Case kit Information for GPs

Palliative care for heart failure patients. Susan Addie

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

Palliative Prescribing - Pain

Palliative Care Impact Survey

Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30

EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Clatterbridge Centre for Oncology

End of Life Care. Dr Anne Garry Consultant in Palliative Medicine

PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

Regional Renal Training

Conservative Management of Uraemia

BREATHLESSNESS MANAGEMENT

Respiratory Secretions. Care in the last 72 hours of life Paul Tait, pharmacist

Implementing the recommendation on medication management and symptom control

ALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug

Using syringe pumps in palliative care

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice

SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:

Care of dying adults in the last days of life. Improving care at the very end of life.

In our patients the cause of seizures can be broadly divided into structural and systemic causes.

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)

Palliative Patient in Emergency Department

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Approach to symptom control near the end-of-life

End Stage Liver Disease Regional Audit Casenote Survey

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

This survey aims to look at individual practice and can be completed by any healthcare professional.

Regional Breathlessness Audit - Case Note Survey. 1. Introduction. Regional Breathlessness Audit - Case Note Survey. 2.

The last days of life in hospital and at home

Understanding pain in 5 minutes

BACKGROUND Measuring renal function :

Policy/Standard Operating Procedure/ Clinical Guideline. ELHT/CP22 Version 5.1. ELHT/CP22 Version 4.1

Syringe Drivers. Back to top

Berkshire West Area Prescribing Committee Guidance

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

INTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT

Planning for the future; A guide to symptom control at end of life in advanced dementia

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

Palliative care for patients with brain cancer


What s New 2003? What new treatments? What have you discontinued? More information please!

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER

Ventilation/End of Life Neuromuscular Disorders. Dr Emma Husbands Consultant Palliative Medicine

Palliative Care. Pocketbook 4

Target audience: The target audience for this guidance are: GPs Care home managers and nurses, District nurses, and Specialist Palliative Care teams.

SCHEDULE 2 THE SERVICES

Breathlessness in advanced disease. February 2017

Pain management in Paediatric Palliative Care. Dr Jane Nakawesi 14 th August 2017

Palliative Care Formulary

Coversheet for Network Site Specific Group Agreed Documentation

Dyspnea. Stephanie Lindsay

Care of the dying in End Stage Kidney Disease (ESKD) - Conservative. Elizabeth Josland Renal Supportive Care CNC St George Hospital

CLINICAL GUIDELINES FOR END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES

Lothian Palliative Care Guidelines POCKET EDITION 2004

Palliative care in long-term conditions Scottish Palliative Care Pharmacists Association

GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline

Managing dying with chronic heart failure

Long Term Care Formulary HCD - 08

CARE OF THE DYING PATIENT WITH ESKD ELIZABETH JOSLAND - RSC CNC

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain

1 (ix) Pain control. What responsibilities do you assume when you prescribe analgesia?

Eastern Health and Social Services Board Palliative Care

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.

Enhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice

Berkshire Adult Palliative Care Guidelines - End of Life Care GL110

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

Analgesia in patients with impaired renal function Formulary Guidance

Transcription:

Anticipatory prescribing and end of life considerations Dr Stephanie Lippett

contents Pain Restlessness/agitation Nausea/vomiting Secretions Syringe driver Anticipatory prescribing Important things to remember

Opiates Not all patients experience pain during their illness but symptoms are unpredictable Guidance suggests diamorphine but alternative opiates can be used Remember to write up sliding scales of doses as this allows the nursing team to step up/step down the analgesia as required

Opiates If the patient is symptomatic remember to give a stat dose of analgesia as well as commencing the syringe driver. When writing up a syringe driver you need to convert all regular and PRN oral doses of opiates taken in the last 24 hours If the patient is on fentanyl-keep the patch on and use PRN s/c opiates for breakthrough.

Opiates Remember to increase the PRN dose of opiates when the regular dose is increased PRN S/C doses = 1/6 th of total daily opiate dose 1/5 th fentanyl patch dose (diamorphine) = 1/6 of total opiate dose PRN doses are usually written up for 4hourly but at the end of life patients can require stat doses more frequently (1-2 hourly) When calculating doses be sensible and round down to a usable dose e.g. if 1/6 th = 6.66mg round down to 5mg

The Syringe Pump Useful in certain circumstances Vomiting patients Patient no longer swallowing For quick symptom control and dose titration Opiate Dose = total 24 hour oral opiate dose/2 (morphine/oxycodone) /3 (diamorphine)(+ any subcut doses). Opiate naive patients- start with PRN dosing and add into syringe driver if needs 2+ PRN doses. Usually stick with same opiate as oral prep

The Syringe Pump Keep same dose fentanyl patch on -replace every 72 hours as normal. Breakthrough doses need to take fentanyl patch into account as well as pump drugs 1/6 pump dose + 1/6 of equivalent opiate dose of patch (diamorph=1/5 fentanyl patch) Add both together to get total breakthrough dose Patch breakthrough dose will remain constant

4 classes of opiates Phenanthrenes- most of the opiates we use codeine/tramadol/morphine/diamorphine /oxycodone Benzomorphans- loperamide Phenylpiperidines- fentanyl/alfentanil/ pethidine Diphenylheptanes- methadone Useful to know in patients with severe allergiescan change out of group

Choice of drug Effectiveness is much the same with all strong opiates Choice is based on cost local guidelines mode of administration availability side effect profile personal choice renal impairment volume in the syringe driver

Which opiate to choose? Recent nice guidelines not prescriptive-person centred care Morphine = cheapest All conversion tables work on morphine equivalent Diamorphine = 1 st line in Rochdale Relatively cheap compared to other opiates Dry powder amps Useful when volume an issue in the syringe driver Simple to work out fentanyl breakthrough dose Various strength vials-5mg/10mg/30mg/100mg/500mgconsider dose patient is on (S/Driver and breakthrough) 1/3 0ral morphine dose- Reduce dose in renal impairment (egfr <50) or use alternative opiate

Which opiate to choose? Oxycodone More expensive Useful if side effects of morphine not tolerated Better renal profile than morphine but still not recommended in end stage renal failure. Reduced dose needs to be considered if egfr<50 1.5-2 x as potent as morphine (some anecdotal evidence suggests equal potency subcut)? Better for bone pain- evidence not convincing Various strength ampules (10mg/ml, 20mg/2ml, 50mg/ml) Volume can be an issue in the syringe driver with larger doses

Which opiate to choose? Fentanyl patches Topical-useful for swallowing issues Less constipating than other opiates (more lipid soluble therefore crosses BBB easier- lower doses required to give same effect of other opiates) Overcomes some compliance issues Sometimes accepted by patients reluctant to take anything with morphine in the name. 12-48 hours to reach max effect-only suitable for stable pain as titrating up the dose not easy 17 hours to clear drug after removal of the patchdrug reservoir. Better renal profile than morphine/oxycodone

Which opiate to choose? Fentanyl/ alfentanil injections Do not rely on the kidney for excretion Recommended when the egfr is <30 Drugs of choice when egfr < 20 Not removed by dialysis

Cost comparison Morphine 10mg/ml 10 amps = 9 30mg/ml 10amps = 9 Diamorphine 10mg 5amps = 15 30mg 5 amps= 14 Oxycodone 10mg/ml 5amps = 8 50mg/ml 5amps = 70 Fentanyl patch 12mcg 5 patches = 12 100mcg 5patches = 58 Fentanyl inj 100mcg/2ml 10 amps = 14 Alfentanil inj 1mg/2ml 10 amps = 7 5mg/10ml 5amps = 16

Drug Prescribing Issues Computer generated oramorph- 6 hourly oramorph dose BUT some patients need another dose after 30-60 mins Out of hours drug availability-anticipate in hours When the opiate dose in the syringe driver increases the dose of the breakthrough opiate may need to be increased- breakthrough doses are calculated 1/6 of the total daily opiate

Things to remember Consider psychological/spiritual/social issues when pain difficult to control symptom control issues -contact hospice for advice/ OPD review.

Anticipatory prescribing Midazolam- 10mg/2ml amps x10 Glycopyrronium- 600mcg/3ml amps x10 (200mcg/1ml amps ok for breakthroughs but use a lot of amps for S/Driver) Levomepromazine 25mg/1ml amps x10 Opiate- opiate naïve = x10amps, if on opiate no. of amps depends on dose needed(need to calculate enough for several days + breakthrough doses)

Nausea and vomiting 50% of patients with advanced cancer experience problems with N&V (Twycross, Introducing Palliative Care. 1999) Think about a reversible cause and manage this Target anti-emetic to suit the most likely cause Consider route of admin-? Need syringe pump

Nausea and vomiting If oral antiemetic working, consider continuing with it subcut-don t fix what isn t broken Nice advocate Individualised anticipatory prescribing Levomepromazine often chosen re duel use for sedation and no incompatibilities unlike some of the anti-emetics

Levomepromazine 2 Other possibilities Metoclopramide- useful when gastric stasis is a problem but shouldn t be used in patients with intestinal obstruction Cyclizine- broad spectrum anti-emetic but can precipitate with large doses of diamorphine and should be used with caution in patients with severe heart failure Haloperidol-useful for drug induced emesis but can precipitate at large concentrations.

Breathlessness Breathlessness = a subjective experience of breathing discomfort 70% of patients with cancer suffer from breathlessness in the last few weeks of life (Twycross, Introducing Palliative Care, 1999) 25% experience severe symptoms in the last week

Management of breathlessness Correct the correctable Antibiotics-infection/COPD Inhalers/nebulizers-bronchospasm Oxygen-hypoxia Steroids-obstruction/ lymphangitis/ asthma Radiotherapy-obstruction Drainage of fluid-ascites/effusion Diuretics-CCF/ascites/ lymphangitis Anticoagulation-PE

Management of Breathlessness Supportive non drug treatments Anxiety management/ psychological support Energy conservation Fan/open window Positional advice Drug treatments Anxiolytics-reduce panic and anxiety Oxygen-not always needed as patient not always hypoxic. Can be subjectively beneficial without hypoxia Drug treatments Opiates-reduce respiratory drive and perception of breathlessness QDS oramorph (+PRN for pain) ¼ PRN dose-mild breathlessness ½ PRN dose moderate breathlessness 100%-150% PRN dosesevere breathlessness Sedation in severe breathlessness/terminal agitation

Opiates Opiates can also be used to help breathlessness-off licence use Dose is the same as the breakthrough PRN dose of whichever opiate is written up for pain relief but can use smaller doses if symptoms not severe. Work by decreasing the rate of breathing (decrease the ventilatory response to hypercapnia/hypoxia and exercise). They do not cause respiratory depression if given orally/im or s/c.

Opiates Because of this mechanism of action they are safe for all end stage breathlessness(including COPD) Initial treatment includes supportive measures like opening windows/fan/repositioning/considering O2 etc. and treating reversible causes with non aggressive measures like nebulizers/dexamethasone Other drugs that can be useful, esp. when anxiety is a large factor, include Lorazepam 0.5mg prn oral/sublingual or midazolam (doses as for restlessness) s/c.

Terminal restlessness Aka- terminal agitation agitated delirium terminal anguish terminal distress Occurs in up to 80% of patients near the end of life and is a collection of signs of central nervous system irritability

Features Decreased level of consciousness restlessness agitation Distressed vocalizing twitching Myoclonic jerking Recurrent fitting Memory loss Disorientation/confusion Hallucinations/paranoia

management Distressing for the family and so it is important to explain and reassure Important to consider an underlying cause as it may be reversible Supportive measures and sedative medication are often needed

Supportive measures Reassure patient and family Familiar surroundings and faces Lighting and noise reduction Risk assessment-ensure patient/carer safety Look for and manage reversible cause Assess medication-is there a need to continue?

Sedative medication Various medications can be used depending on symptoms and co-existing problems Benzodiazepines(BDZ)- diazepam/lorazepam/midazolam/temazepam- useful for anxiety and to aid sleep Levomepromazine- useful for agitation/paranoia esp. where antiemetic required. NB sedative dose higher than usual antiemetic dose (25-200mg)

Sedative medication Haloperidol-useful for agitation/paranoia/fear esp. where antiemetic needed Barbiturates(phenobarbitone)-last resort medications. Useful for severe intractable insomnia/fitting/bdz paradoxical agitation

Midazolam Chosen as one of the end of life drugs because of its various uses Used for terminal restlessness/myoclonal jerks and fitting Doses differ for the different uses-doses start lower for terminal restlessness/myoclonic jerks.

Respiratory secretions. Respiratory secretions in the last days or hours of life are not uncommon. They can be distressing for relatives but are unlikely to distress the patient unless they are pronounced and the patient has awareness of them. These secretions are difficult to treat, once established, therefore attempts to PREVENT them can be more effective than treating an established problem.

General measures. There are non-medical measures that might help: REPOSITIONING can be helpful. Try tipping the bed head-up if the rattle is in the pharynx, to assist drainage. REASSURANCE and EXPLANATION to relatives. The relatives may be acutely aware of any changes while they wait with their loved one. Explanation that, mostly, secretions won t be distressing the patient can help.

Medical (drug) measures. Anticholinergic (antimuscarinic) drugs will reduce secretion of fluids like saliva and intestinal juices. THEY DO NOT REMOVE SECRETIONS THAT ARE ALREADY PRESENT. There is only moderate to low evidence from studies that pharmacological treatments help secretions at end-of-life. Remember: they will cause a dry mouth, so could add symptoms to the patient. Good on-going mouth care is important.

Anticholinergic drugs. GLYCOPYRRONIUM. This is non-sedating. HYOSCINE HYDROBROMIDE. This is sedating. HYOSCINE BUTYLBROMIDE (e.g. Buscopan). This is non-sedating.

Glycopyrronium. Glycopyrronium is given as s/c doses 200 micrograms (mcg) PRN up to every four hours and used in syringe driver. Maximum 1200 mcg/24 hours. More potent than hyoscine hydrobromide as an antisecretory but in practice has about the same efficacy as it. Either will REDUCE the rattle in about 1/2 to 2/3 of patients. Lower doses can be effective if renal impairment coexists. It is not sedating.

Hyoscine hydrobromide. Hyoscine hydrobromide is given s/c 400mcg PRN up to every 4 hours and can be used in a syringe driver. Maximum 2000 mcg/24 hours. Similar efficacy to Glycopyrronium but it is SEDATING.

What if secretions persist despite medications? IF MAXIMAL DOSES of either Glycopyrronium or Hyoscine DO NOT WORK, THEN DRUG MEASURES PROBABLY WON T. It might be worth considering a swap, but using both together is unlikely to bring more benefit and is more likely to cause side effects.

Suction. Suction should be considered only in severe cases where the secretions are accessible. The patient needs to be unconscious to tolerate it and it could be argued that they would be unlikely to be distressed by the secretions Anecdotally, suction seems to stimulate more secretion itself.

Things to remember Terminal restlessness-very distressing for families. Patients can deteriorate very quicklyanticipatory drugs at home. Carry DNACPR form/prescribing authorisation sheets in bag -saves having to go and find one Consider stage of illness - before referring on for management and treatment if PPC is home

Things to remember Fitting risk- starting dose of midazolam in driver is higher (20-30mg) as is PRN dose (increase range to 10mg). Drug provision- need to take into account concentration and volume in syringe pump (e.g. glycopyrronium) as well as PRN doses needed (amount of vials prescribed). Compatibility/ volume issues -2 syringe drivers

Drug Prescribing Issues Drug provision-need to consider how long the drug will last for-how many vials in the syringe pump + breakthrough doses Anticipatory prescribing-need to consider current oral dose and range of dose when prescribing Consider if the drug is working for the pain if needing PRNs +++ (? Neuropathic agent/ NSAID needed) Don t automatically increase syringe driver dose

Drug Prescribing Issues Consider drug availability out of hours-prescribe enough to last until in hours Remember to leave the prescribing advice in the house so meds can be administered and regularly review (re-sign monthly) Take the prescribing advice/conversion tables with you when you get called out to a terminally ill patient

finally Some important things to remember The advice is a guide and not set in stone-nice guidelines advise individualised prescribing Prescribe in anticipation as symptoms are unpredictable and patients deteriorate quickly Prescribe a range of doses when writing up the medications and indicate a starting dose-saves time Remember to recalculate opiate PRN doses when the regular doses are changed

finally Some important things to remember Remember to regularly update special notes with BARDOC-can undo all the good work done to achieve a good death if forgotten DOLS/DOLIC-patients who die under a deprivation of liberty order no longer automatically need referral to the coroner